ASX:PXS Pharmaxis (PXS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Pharmaxis Stock (ASX:PXS) 30 days 90 days 365 days Advanced Chart Get Pharmaxis alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume721,139 shsAverage VolumeN/AMarket Capitalization$20.23 millionP/E RatioN/ADividend Yield6.41%Price TargetN/AConsensus RatingN/A Company OverviewPharmaxis Ltd, a clinical stage drug development company, engages in the research, development, and commercialization of healthcare products for the treatment of fibrotic and inflammatory diseases worldwide. It operates through Mannitol Respiratory Business and New Drug Development segments. The company provides Bronchitol, an inhaled dry powder for the treatment of cystic fibrosis; and Aridol, a lung function test for the treatment of asthma. It's product pipeline comprises oral pan-Lysyl Oxidase Inhibitors (LOX) targeting myelofibrosis and other cancers; topical pan-LOX inhibitors targeting skin scarring after events such as accidents, surgery, and burns; selective Lysyl Oxidase Like Inhibitors (LOXL2) targeting chronic fibrotic diseases including kidney, pulmonary, liver, and cardiac fibrosis; and semicarbazide-sensitive amine oxidase for neuro inflammatory diseases. The company also offers Orbital, a dry powder inhaler to deliver high drug doses to lungs. Pharmaxis Ltd was incorporated in 1998 and is headquartered in Frenchs Forest, Australia.Read More… Receive PXS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pharmaxis and its competitors with MarketBeat's FREE daily newsletter. Email Address PXS Stock News HeadlinesCanaccord Genuity Sticks to Their Buy Rating for Pharmaxis Ltd (SNT)March 14, 2025 | markets.businessinsider.comPharmaxis Ltd Highlights Product Pipeline and RisksOctober 30, 2024 | markets.businessinsider.comWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how to trade it, this phase brings the most potential. We’re now in that window. A free workshop outlines how a proven system is targeting daily wins, passive income, and explosive upside through curated altcoin picks. Whether you're new to crypto or looking to catch the next move with confidence, this is your roadmap. And just for showing up, you’ll receive $10 in real Bitcoin. Don’t miss it.May 24, 2025 | Crypto Swap Profits (Ad)Syntara bolsters financial position with R&D tax incentiveDecember 4, 2023 | proactiveinvestors.com.auHere's Why Shareholders Should Examine Pharmaxis Ltd's (ASX:PXS) CEO Compensation Package More CloselyNovember 21, 2023 | finance.yahoo.comFIVE at FIVE AU: ASX down 1.5% on Middle East fears; employment slowsOctober 19, 2023 | proactiveinvestors.com.auPharmaxis to focus on clinical-stage drug developmentOctober 3, 2023 | proactiveinvestors.com.auPharmaxis to undergo major company restructure and rebrand as Syntara; sells mannitol businessOctober 3, 2023 | proactiveinvestors.com.auSee More Headlines PXS Stock Analysis - Frequently Asked Questions How were Pharmaxis' earnings last quarter? Pharmaxis Ltd (ASX:PXS) issued its quarterly earnings results on Thursday, February, 14th. The company reported ($0.03) earnings per share for the quarter. Pharmaxis had a negative trailing twelve-month return on equity of 143.13% and a negative net margin of 161.24%. What other stocks do shareholders of Pharmaxis own? Based on aggregate information from My MarketBeat watchlists, some other companies that Pharmaxis investors own include Atara Biotherapeutics (ATRA), CRISPR Therapeutics (CRSP), Acasti Pharma (ACST), American Woodmark (AMWD), Guardion Health Sciences (GHSI), Incannex Healthcare (IHL) and XPO (XPO). Company Calendar Last Earnings2/14/2019Today5/24/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Drug Manufacturers - Specialty & Generic Sub-IndustryTransportation Current SymbolASX:PXS CIKN/A Webwww.pharmaxis.com.au Phone+61-2-94547200FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)A($0.02) Trailing P/E RatioN/A Forward P/E RatioN/A P/E Growth0.21Net Income$-18,430,000.00 Net Margins-161.24% Pretax MarginN/A Return on Equity-143.13% Return on Assets-48.68% Debt Debt-to-Equity RatioN/A Current Ratio7.21 Quick Ratio14.73 Sales & Book Value Annual Sales$11.89 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow1.32 Book ValueA$0.00 per share Price / BookN/AMiscellaneous Outstanding Shares722,610,000Free FloatN/AMarket Cap$20.23 million OptionableNot Optionable Beta0.64 7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report This page (ASX:PXS) was last updated on 5/24/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored$19 for a FULL YEAR of stock picks?!Invest in Musk's AI Play With Just $100 You don't need deep pockets to ride the next wave of AI wealth. ...Behind the Markets | SponsoredWe’ve Entered the Most Bullish Phase of the CycleIt happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredAfter Monday, price goes up 600% (hurry)Right now, for a limited time… You can get up to 52 Money Monday trades for just $7! Thanks to Wall Street’...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pharmaxis Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Pharmaxis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.